Fibrosis-Driven Cardiovascular Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease: Emerging Links With Atherosclerotic Cardiovascular Disease

Nakul Mahajan, Nazdeep Kaur, Samar Pal S Sandhu, Vyoma Patel, Hunardeep Kaur Boparai, Kanwarmandeep Singh, FNU Rajinderpal Singh · 2026

Read Fibrosis-Driven Cardiovascular Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease: Emerging Links With Atherosclerotic Cardiovascular Disease by Nakul Mahajan, Nazdeep Kaur, Samar Pal S Sandhu, Vyoma Patel, Hunardeep Kaur Boparai, Kanwarmandeep Singh, FNU Rajinderpal Singh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13625605.txt.

Description

Nakul Mahajan and co-authors review how liver scarring drives heart risk in fatty liver disease in this 2026 paper. The disease, now called MASLD, is a whole-body metabolic disorder. Fat in the liver was long treated as its defining mark.

Fresh evidence suggests scarring, not fat alone, best predicts heart and vessel harm. That shift has drawn interest in adding fibrosis checks to heart risk scoring. The review gathers the emerging links between liver fibrosis and artery disease. Shared drivers like insulin resistance and inflammation run through both organs. Clinicians who grade liver scarring may catch heart risk earlier. The paper maps a fast-changing corner of preventive care.

Catalog record

CREATORNakul Mahajan, Nazdeep Kaur, Samar Pal S Sandhu, Vyoma Patel, Hunardeep Kaur Boparai, Kanwarmandeep Singh, FNU Rajinderpal Singh
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13625605

Browse the full library · About the Tower of Babel